NantKwest, Inc., a clinical-stage immunotherapy biotechnology company, develops immunotherapeutic treatments for cancer, infectious diseases, and inflammatory diseases in the United States. The company develops activated natural killer cell, a natural killer cell-line and genetically modified derivative capable of killing cancer and virally infected cells; and NANT cancer vaccine, a personalized therapy that utilizes its off-the-shelf natural killer cells. It is also developing high-affinity natural killer product candidates primarily for the treatment of various cancers; and target activated natural killer product candidates to treat hematological malignancies and solid tumors. NantKwest, Inc. has a co-development agreement with Altor Bio Science Corporation to collaborate on the development of therapeutic applications combining the company's proprietary natural killer cells with Altor's ALT-801 and/or ALT-803 products. The company was formerly known as Conkwest, Inc. and changed its name to NantKwest, Inc. in July 2015. NantKwest, Inc. was founded in 2002 and is headquartered in San Diego, California.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Phone858-633-0300
Debt
Current Ratio3.31
Quick Ratio3.31
Price-To-Earnings
Sales & Book Value
Annual Sales$50,000.00
Price / Sales2,170.90
Price / Cash FlowN/A
Price / Book0.50
Profitability
Net Income$-96,420,000.00
Net Margins-198,790.38%
Return on Assets-46.28%
Miscellaneous
Employees139
OptionableOptionable
Nantkwest (NASDAQ:NK) Frequently Asked Questions
What is Nantkwest's stock symbol?
Nantkwest trades on the NASDAQ under the ticker symbol "NK."
How were Nantkwest's earnings last quarter?
Nantkwest Inc (NASDAQ:NK) issued its earnings results on Wednesday, November, 7th. The biotechnology company reported ($0.30) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.37) by $0.07. The biotechnology company had revenue of $0.03 million for the quarter. Nantkwest had a negative return on equity of 54.20% and a negative net margin of 198,790.38%. View Nantkwest's Earnings History.
When is Nantkwest's next earnings date?
What price target have analysts set for NK?
2 equities research analysts have issued twelve-month price objectives for Nantkwest's shares. Their forecasts range from $2.00 to $3.50. On average, they expect Nantkwest's share price to reach $2.75 in the next year. This suggests a possible upside of 100.7% from the stock's current price. View Analyst Price Targets for Nantkwest.
What is the consensus analysts' recommendation for Nantkwest?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Nantkwest in the last year. There are currently 2 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Nantkwest.
Has Nantkwest been receiving favorable news coverage?
Press coverage about NK stock has been trending somewhat negative on Wednesday, InfoTrie reports. The research group scores the sentiment of media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Nantkwest earned a news impact score of -1.2 on InfoTrie's scale. They also gave headlines about the biotechnology company a news buzz of 5.0 out of 10, indicating that recent media coverage is somewhat likely to have an effect on the company's share price in the next few days.
Who are some of Nantkwest's key competitors?
Some companies that are related to Nantkwest include Scholar Rock (SRRK), Agenus (AGEN), Krystal Biotech (KRYS), CASI Pharmaceuticals (CASI), Nightstar Therapeutics (NITE), Avrobio (AVRO), Replimune Group (REPL), Cellular Biomedicine Group (CBMG), MeiraGTx (MGTX), Voyager Therapeutics (VYGR), Gamida Cell (GMDA), Translate Bio (TBIO), Eiger Biopharmaceuticals (EIGR), Sutro Biopharma (STRO) and Adverum Biotechnologies (ADVM).
Who are Nantkwest's key executives?
Nantkwest's management team includes the folowing people:
- Dr. Patrick Soon-Shiong FRCS (C), M.D., FACS, Exec. Chairman & CEO (Age 65)
- Dr. Barry J. Simon, Pres, Chief Admin. Officer & Exec. Director (Age 53)
- Mr. Richard J. Tajak, Consultant (Age 65)
- Ms. Sonja Nelson, CFO & Principal Financial Officer (Age 45)
- Mr. David J. Pyrce, Chief Commercial Officer and Sr. VP of Innovation & Investor Relations (Age 61)
When did Nantkwest IPO?
(NK) raised $150 million in an initial public offering (IPO) on Tuesday, July 28th 2015. The company issued 7,000,000 shares at a price of $20.00-$23.00 per share. BofA Merrill Lynch, Citigroup, Jefferies and Piper Jaffray acted as the underwriters for the IPO and MLV & Co. was co-manager.
How do I buy shares of Nantkwest?
Shares of NK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Nantkwest's stock price today?
One share of NK stock can currently be purchased for approximately $1.37.
How big of a company is Nantkwest?
Nantkwest has a market capitalization of $107.75 million and generates $50,000.00 in revenue each year. The biotechnology company earns $-96,420,000.00 in net income (profit) each year or ($1.20) on an earnings per share basis. Nantkwest employs 139 workers across the globe.
What is Nantkwest's official website?
How can I contact Nantkwest?
Nantkwest's mailing address is 3530 JOHN HOPKINS COURT, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-633-0300 or via email at [email protected]
MarketBeat Community Rating for Nantkwest (NASDAQ NK)
MarketBeat's community ratings are surveys of what our community members think about Nantkwest and other stocks. Vote "Outperform" if you believe NK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NK will underperform the S&P 500 over the long term. You may vote once every thirty days.
